Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Colorectal Neoplasms 260Carcinoma, Non-Small-Cell Lung 125Glioblastoma 105Breast Neoplasms 104Ovarian Neoplasms 96Carcinoma, Hepatocellular 88Brain Neoplasms 71Rectal Neoplasms 69Neoplasm Metastasis 69Lung Neoplasms 65Colonic Neoplasms 58Neoplasms 57Glioma 52Fallopian Tube Neoplasms 44Carcinoma, Renal Cell 36Gliosarcoma 31Pancreatic Neoplasms 30Melanoma 27Liver Neoplasms 26Stomach Neoplasms 21Astrocytoma 21Adenocarcinoma of Lung 21Recurrence 20Kidney Neoplasms 19Colorectal Cancer Metastatic 17Triple Negative Breast Neoplasms 16Esophageal Neoplasms 15Uterine Cervical Neoplasms 14Sarcoma 13Prostatic Neoplasms 13

Interventions

tremelimumab 1durvalumab 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Platinum-resistant Recurrent Ovarian Cancer × Bevacizumab × Clear all
NCT06509971 2024-07-19

A Study of QL1706 (an Anti-PD-1/CTLA-4 Combined Antibody) Combined With Albumin-bound Paclitaxel and Bevacizumab in the Treatment of Platinum-resistant Recurrent Ovarian Cancer

West China Second University Hospital

Phase 2 Not yet recruiting
39 enrolled
Gynecologic

Platinum-resistant Recurrent Ovarian Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡